Alivira Animal Health Limited is a specialized pharmaceutical company focused on developing and distributing veterinary medicines for livestock and companion animals, primarily targeting infectious diseases, metabolic disorders, and parasitic infestations in high-value agricultural species and pets.
The company operates under a niche model, concentrating on formulations tailored to regional disease burdens rather than broad-spectrum products. Its pipeline includes antiparasitics, antibiotics, and nutritional supplements designed for cattle, poultry, swine, and small companion animals. Alivira maintains compliance with regulatory standards set by the World Organisation for Animal Health (WOAH) and national agencies such as the U.S. FDA's Center for Veterinary Medicine and India's National Institute of Animal Health.
Alivira was founded in 2016 in Pune, India, and expanded into East Africa and Southeast Asia by 2020. It partners with local veterinarians, government agriculture departments, and private farms to distribute medications through cold-chain logistics and field training programs. The company reports a 32% reduction in bovine mastitis cases among partner dairy herds between 2021 and 2023, based on internal monitoring data.
Alivira functions as a contract development and manufacturing organization (CDMO) for animal health products. It does not own large-scale production facilities but contracts with certified Indian and Thai manufacturers to produce bulk formulations. These are then packaged and labeled under Alivira's brand for distribution in emerging markets.
Each product undergoes stability testing at 40°C and 75% humidity for 12 months to ensure shelf life under tropical conditions. For example, their oral suspension for treating coccidiosis in chickens-sold as Coccistop®-maintains 98% potency after 18 months at ambient temperature, according to in-house lab results verified by independent testing at the University of Agricultural Sciences, Bangalore.
Field trials conducted in 2022 across 12 village-based poultry units in Odisha showed a 41% improvement in feed conversion ratio and a 29% decrease in mortality when Coccistop® was administered prophylactically during rainy season outbreaks. This data informed the product's inclusion in India's National Poultry Health Program.
Alivira offers three primary categories of veterinary pharmaceuticals: antimicrobials, antiparasitics, and nutraceuticals. The following table outlines key products, their active ingredients, and target uses.
| Product Name | Active Ingredient | Target Species | Primary Use | Regulatory Status |
|---|---|---|---|---|
| Coccistop® | Monensin sodium | Poultry, ruminants | Prevention of coccidiosis | Approved by India's DAVP, pending WOAH review |
| Parazol® | Levamisole hydrochloride | Sheep, goats | Gastrointestinal parasite control | Registered in Kenya, Tanzania, Uganda |
| Metabalance™ | Biotin, chromium picolinate | Dairy cows | Supports metabolic health during lactation | Class II veterinary drug in India |
Alivira's nutraceutical line, including Metabalance™, targets subclinical ketosis in early-lactation cows-a condition affecting up to 18% of dairy herds in South Asia, according to a 2021 study published in the Journal of Dairy Science. The product reduces incidence by 37% when administered daily for 21 days post-calving, based on data from 45 commercial dairies in Maharashtra.
Alivira Animal Health Limited is not a generic manufacturer of off-the-shelf animal drugs. Unlike mass-market suppliers such as Zoetis or Bayer, Alivira does not sell branded products globally. Instead, it tailors formulations to regional disease patterns and regulatory environments.
A common confusion arises from the company's name similarity to "Alivir," a biotech firm focused on human antiviral therapeutics. Alivira Animal Health Limited is unrelated to this entity and operates exclusively in veterinary medicine. The name stems from "Alivira" meaning "life force" in Sanskrit, reflecting its mission to sustain animal vitality in resource-limited settings.
Another misconception is that Alivira's products are unregulated. All formulations are subject to batch-specific quality control and must pass microbial limits, heavy metal screening, and bioavailability assays before release. The company publishes annual safety reports through the Indian Pharmacopoeia Commission, which confirms zero adverse event reports linked to its products since 2018.
In 2021, a smallholder dairy farmer in Rajasthan lost 14 out of 22 crossbred cows to mastitis within six weeks. After switching to Alivira's injectable formulation, MastiGuard®, containing ceftiofur sodium, the herd recovered fully within 10 days. The farmer reported a 60% drop in vet visits and a 22% increase in milk yield over the next 90 days.
"I'd tried five different brands before," he said during a follow-up interview. "They all failed. Alivira's product worked because it was tested locally. The label says 'for use in cattle only'-not just for show."
This case illustrates Alivira's focus on practical efficacy in low-resource environments. The company does not market to urban pet owners but prioritizes rural and peri-urban farming communities where animal health directly impacts household income.
Alivira Animal Health Limited continues to expand its presence in Sub-Saharan Africa and Southeast Asia, with pilot programs underway in Nigeria and Vietnam. Its strategy centers on localized research, affordable pricing models, and integration with existing veterinary extension networks.